Lotus Pharmaceuticals, Inc.

16 Cheng Zhuang Road

Feng Tai District

Beijing 100071 China

86-10-63899868

July 23, 2008

‘CORRESP’

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jennifer Riegel

Mail Stop 6010

Re: Lotus Pharmaceuticals, Inc.

Registration Statement on Form S-1

File No. 333-150879

Ladies and Gentlemen:

The undersigned registrant hereby requests acceleration of the effective date of the above-captioned Registration Statement to Friday, July 25, 2008 at 10:00 A.M., Eastern time, or as soon thereafter as is practicable.

The undersigned registrant acknowledges that:

• Should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

• The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

• The company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The undersigned also acknowledges to the Staff its awareness of its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended.

Very truly yours,

/s/ Adam Wasserman

Adam Wasserman

Chief Financial Officer